|
|
|
|
This Web site is supported by educational grants from Genentech and GlaxoSmithKline. |
|
|
|
|
|
|
|
|
|
|
|
|
|
Home |
 |
|
| News Updates! |
The appearance of news releases and external hyperlinks does not constitute endorsement by PER of the news release; linked Web sites; or information, products, or positions contained therein. |
Glaxo tests Tykerb vs Herceptin in early cancer
| Novelos Therapeutics Announces Positive Results in Ongoing Phase 2 Neoadjuvant Breast Cancer Trial at MUSC Hollings Cancer Center
| FDA Panel Doesn't Back Expanded Use Of Fentora
| OncoVista seeks FDA approval to market breast-cancer detection device
| BRCA Mutations Don't Spot All High-Risk Women
| EU backs Glaxo's breast cancer drug with warnings
|
Read More >> |
| Journal Watch Updates! |
| Lapatinib monotherapy demonstrated activity in patients with ErbB2-positive, locally advanced or metastatic breast cancer as first-line therapy, with a manageable toxicity profile. | | May 16, 2008, 11:12 AM | J Clin Oncol | PubMed |
|
| 2. Retrospective study of 15 international breast cancer trials with a median follow-up of 13 years identified specific clinical and prognostic features that differentiated between infiltrating lobular carcinoma and infiltrating ductal carcinoma. | | May 16, 2008, 11:11 AM | J Clin Oncol | PubMed |
|
| The combination of trastuzumab and pertuzumab demonstrated activity in patients with metastatic breast cancer with disease progression on prior trastuzumab therapy, with associated cardiac toxicity remaining primarily asymptomatic. | | May 16, 2008, 11:10 AM | Clin Cancer Res | PubMed |
|
| Retrospective study of patients with invasive breast cancer who underwent complete axillary dissection identified pathological features predictive of a low probability of having four or more involved nodes, leading to development of a nomogram to aid treatment decision making. | | May 16, 2008, 11:08 AM | J Clin Oncol | PubMed |
|
Read More >> |
|
Journals
|
 |
Clinical Breast Cancer
December 2007
(Vol. 7 No. 11)
Table of Contents |
|
Interactive Case Studies
|
 |
1 AMA PRA Category 1 Credit™
Expiration date: December 28, 2008 |
| Interactive Case Study: Treatment Options for a Patient With Metastatic Breast Cancer Who Cannot Receive a Conventional Taxane
|
|
Interviews with Key Opinion Leaders
|
 |
Medical Director, US Oncology Research, Houston, TX |
| Watch Video |
|
 |
Professor of Oncology, Université Libre de Bruxelles, Department Head, Medicine, Jules Bordet Institute, Belgium |
| Watch Video |
|
 |
Professor of Medical Statistics & Epidemiology, University of Oxford Oxford, United Kingdom |
| Watch Video |
|
|
|
|
| What's
New Online! |
 |
Vol. 5, No. 2
1 AMA PRA Category
1 Credit™
Expiration date: May 6, 2009 |
 |
|
 |
March 2008
1 AMA
PRA Category 1 Credit™
Expiration date: April 25, 2009
|
 |
March 2008
2 AMA PRA Category
1 Credits™
Expiration date: April 15, 2009 |
|
|
|
|
|
